# 21 C.F.R. § 314.71 (2026): Procedures for submission of a supplement to an approved application

> Federal · Regulations · In force

URL: https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_71

## Section

- **Citation:** 21 C.F.R. § 314.71 (2026)
- **Heading:** Procedures for submission of a supplement to an approved application
- **Jurisdiction:** Federal
- **Kind:** Regulations
- **Status:** In force
- **Text as of:** September 30, 2026
- **Source:** Compiled text
- **Location:** Title 21 CFR: Food and Drugs / Chapter I / Part 314 / Subpart B / § 314.71: § 314.71   Procedures for submission of a supplement to an approved application.

## Text

(a) Only the applicant may submit a supplement to an application. (b) All procedures and actions that apply to an application under § 314.50 also apply to supplements, except that the information required in the supplement is limited to that needed to support the change. A supplement is required to contain an archival copy and a review copy that include an application form and appropriate technical sections, samples, and labeling; except that a supplement for a change other than a change in labeling is required also to contain a field copy. (c) All procedures and actions that apply to applications under this part, including actions by applicants and the Food and Drug Administration, also apply to supplements except as specified otherwise in this part. [50 FR 7493, Feb. 22, 1985, as amended at 50 FR 21238, May 23, 1985; 58 FR 47352, Sept. 8, 1993; 67 FR 9586, Mar. 4, 2002; 73 FR 39609, July 10, 2008]

## Nearby sections

- [21 C.F.R. § 314.50 (2026) Content and format of an NDA.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_50.md)
- [21 C.F.R. § 314.52 (2026) § 314.52   Notice of certification of invalidity, unenforceability, or noninfringement of a patent.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_52.md)
- [21 C.F.R. § 314.53 (2026) § 314.53   Submission of patent information.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_53.md)
- [21 C.F.R. § 314.54 (2026) § 314.54   Procedure for submission of a 505(b)(2) application requiring investigations for approval of a new indication for, or other change from, a listed drug.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_54.md)
- [21 C.F.R. § 314.55 (2026) § 314.55   Pediatric use information.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_55.md)
- [21 C.F.R. § 314.56 (2026) § 314.56   Nonprescription drug product with an additional condition for nonprescription use (ACNU).](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_56.md)
- [21 C.F.R. § 314.60 (2026) § 314.60   Amendments to an unapproved NDA, supplement, or resubmission.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_60.md)
- [21 C.F.R. § 314.65 (2026) § 314.65   Withdrawal by the applicant of an unapproved application.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_65.md)
- [21 C.F.R. § 314.70 (2026) § 314.70   Supplements and other changes to an approved NDA.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_70.md)
- [21 C.F.R. § 314.71 (2026) § 314.71   Procedures for submission of a supplement to an approved application.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_71.md)
- [21 C.F.R. § 314.72 (2026) § 314.72   Change in ownership of an application.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_72.md)
- [21 C.F.R. § 314.80 (2026) § 314.80   Postmarketing reporting of adverse drug experiences.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_80.md)
- [21 C.F.R. § 314.81 (2026) Other postmarketing reports.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_81.md)
- [21 C.F.R. § 314.90 (2026) § 314.90   Waivers.](https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_90.md)

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/statutes/CFR_T21_P314_S314_71. Check the current official text before relying on it. Not legal advice.
